ISPOR 12th European Congress Released Presentations
 

RELEASED PRESENTATIONS

1st Plenary Session Video
PLENARY SESSIONS
 
FIRST PLENARY SESSION: Health Care Reimbursement Systems in Europe: Learning from Each Other
 
Health Care Reimbursement Systems in Europe: Learning from Each Other
Claude Le Pen, PhD
Professor of Health Economics, University of Paris-Dauphine and Expert, IMS Health, Puteaux, France
 
Health Care Reimbursement Systems in Europe: Learning from Each Other
Laurent Degos MD, PhD
Chairman, Haute Autorité de Santé (HAS), Saint-Denis La Plaine, France
 
Health Care Reimbursement Systems in Europe: Learning from Each Other
Sir Michael Rawlins MD, FRCP, FMedSci
Chairman, National Institute of Health & Clinical Excellence (NICE), London, UK
 
Health Care Reimbursement Systems in Europe: Learning from Each Other
Peter Sawicki MD, PhD
Director, Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany
 
SECOND PLENARY SESSION: Performance-based Agreements - Theory to Practice
 
Performance-based Agreements - Theory to Practice
Gérard de Pouvourville PhD
Professor and Chair of Health Economics, ESSEC Business School, Cergy-Pontoise, France
 
Performance-based Agreements - Theory to Practice
Sean D. Sullivan PhD, RPh
Professor of Pharmacy and Public Health and Director, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA
 
Performance-based Agreements - Theory to Practice
Jens Grueger PhD
Vice President, Head Global Market Access Primary Care, Pfizer Ltd, Tadsworth, Surrey, UK
 
THIRD PLENARY SESSION: Involving Patients/Citizens in Health Care Decisions
 
Patient, Carer and Public Involvement In NICE Decision-Making
Victoria Thomas MSc
Associate Director, Patient and Public Involvement, National Institute for Health and Clinical Excellence (NICE), London, UK
 
Role of Patient Advocacy Groups in Health Care Policy Decisions
Nicola Bedlington
Executive Director, European Patients’ Forum, Brussels, Belgium
 
Involving Citizens in Health Care Decisions in Sweden
Ulf Persson PhD
Research Director, The Institute for Health Economics, Lund, Sweden

PODIUM AND POSTER PRESENTATIONS
 

For contributed research podium and poster abstracts and released slide or poster presentations for the ISPOR 12th Annual European Congress, see: ISPOR Outcomes Research Digest an electronic database of over 13,500 research papers presented at ISPOR Annual International Meetings, ISPOR Annual European Congresses, and biennial ISPOR Asia-Pacific & Latin America Conferences from 1998 to date.

  • ISPOR Outcomes Research Digest:  http://www.ispor.org/research_study_digest/research_index.asp

  • Under Meeting select 12th Annual European Congress – Paris, France – 2009, then Search for all available research podium and poster abstracts and presentations from the meeting.  Alternatively search by disease/disorder, topic or subtopic

EDUCATIONAL SYMPOSIA
 

New Developments in Health Technology Assessment (HTA): How does this ImpacT Health Economics and Outcomes Research (Sponsored by IMS)

http://www.ispor.org/images/j0115844.gif Register for Proceedings
 

COMPARATIVE EFFECTIVENESS: CAN THE AGENCIES’ DEMANDS BE MET? (Sponsored by UBC and Shire)

http://www.ispor.org/images/j0115844.gif For Proceedings, Email: analytics@unitedbiosource.com.
 

Regulatory Review and Health Technology Assessment (HTA) - Opportunities and Limitations of an Integrative Approach (Sponsored by European Federation of Pharmaceutical Industries and Associations – EFPIA)

 
Compliance and Persistence: Capturing the Economic Benefits (Sponsored by Amgen)

ISPOR CHAPTER FORUMS

 
THE ROLE OF SCIENTIFIC EVIDENCE IN HEALTH CARE DECISION-MAKING IN CENTRAL/EASTERN EUROPE & EVIDENCE BASED PHARMACOTHERAPY
» ISPOR Hungary Regional Chapter
» ISPOR Israel Regional Chapter
» ISPOR Serbia Regional Chapter
» ISPOR Slovakia Regional Chapter
» ISPOR Croatia Regional Chapter
» ISPOR Czech Republic Regional Chapter
   

QUALITY OF LIFE AND KNOWLEDGE ABOUT TOBACCO SMOKING TOXICITY AMONG SMOKERS OR SMOKERS WITH CHRONIC OBSTRUCTIVE LUNG DISEASES IN POLAND AND GREECE

» ISPOR Poland Regional Chapter
» ISPOR Greece Regional Chapter
   
GENERICS AND BIOANALOGS: NEW CHALLENGES ISPOR RUSSIA REGIONAL CHAPTER
» Economy of Equivalence: New Challenge
» Biosimilars: General Issues, Approaches to Regulation in Europe
» Healthcare in Russia: Trends and Prospects – Import substitution and Innovative development of Russian Pharmaceutical Industry
» Brand-Name and Generic Drugs – What to Choose?

ISSUE PANELS

IP1: THE UK NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE): NEW DEVELOPMENTS

THE ERG PERSPECTIVE
Matt D Stevenson PhD

Technical Director, School for Health and Related Research Technology Assessment (ScHARR – TAG), University of Sheffield, Sheffield, UK

RECOMMENDATIONS FOR RESEARCH PLANNING
Sorrel E Wolowacz PhD
Senior Health Economist, RTI Health Solutions, Manchester, UK

IP2: PHARMACEUTICAL POLICIES IN EUROPEAN COUNTRIES: AIMING AT COST CONTAINMENT, COST-EFFECTIVENESS OR EQUITY?

PHARMACEUTICAL POLICIES IN EUROPEAN COUNTRIES: THE NETHERLANDS
Marc Koopmanschap PhD
Researcher, Institute for Medical Technology Assessment, Erasmus MC, Rotterdam, The Netherlands

Pharmaceutical Policies in European Countries: Recent Experiences in England
John Hutton PhD
Professor of Health Economics, Department of Health Sciences – Health Economics, University of York, York, UK

IP3: THE DEVIL IS IN THE DETAILS: INTERNATIONAL COMPARISON OF TECHNOLOGY ASSESSMENT PROCESSES AND PAYER UPTAKE OF PERSONALIZED MEDICINE AND IMPLICATIONS FOR THE FIELD

THE DEVIL IS IN THE DETAILS: INTERNATIONAL COMPARISON OF TECHNOLOGY ASSESSMENT PROCESSES AND PAYER UPTAKE OF PERSONALIZED MEDICINE AND IMPLICATIONS FOR THE FIELD
Eric C Faulkner MPH, Senior Director, Pricing & Reimbursement, RTI Health Solutions, Research Triangle Park, NC, USA; Lieven Annemans PhD, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; Uwe Siebert MD, MPH, MSc, Professor, UMIT – University for Health Sciences, Medical Informatics and Technology, Hall i.T, Austria; Katherine Payne PhD, Senior Research Fellow, University of Manchester, Manchester, UK

IP4: WHAT SHOULD BE THE ROLE OF PATIENT PREFERENCES IN MAKING HEALTHCARE RESOURCE ALLOCATION DECISIONS?

WHAT SHOULD BE THE ROLE OF PATIENT PREFERENCES IN MAKING HEALTHCARE RESOURCE ALLOCATION DECISIONS?
Mark J Sculpher PhD
Professor of Health Economics, Centre for Health Economics, University of York, York, UK

Using Preferences in Decision Making
Deborah A. Marshall PhD
Associate Professor, Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada

IP5: PATIENT-REPORTED OUTCOMES AS A STANDARD APPROACH FOR HEALTH CARE POLICY MAKERS

IMPLEMENTATION OF PROS IN COOPERATIVE GROUPS
Carolyn Gotay PhD
Professor, University of British Columbia, Vancouver, BC, Canada

PATIENT REPORTED OUTCOMES (PROS) IN A CLINICAL TRIAL SETTING: IMPLICATIONS AND CHALLENGES
Chantal Quinten MSc
Researcher, Quality of Life Department, EORTC, Brussels, Belgium

IP6: SOCIETAL VERSUS PAYER PERSPECTIVES FOR COST-EFFECTIVENESS ANALYSIS: CAN WE JUSTIFY VARIATION BETWEEN DECISION MAKERS?

ARGUMENTS FOR A SOCIAL PERSPECTIVE
Bengt Jonsson PhD
Professor, Department of Economics, Stockholm School of Economics, Stockholm, Sweden

IP8: IQWIG AND THE EFFICIENCY FRONTIER – HOW CAN WE MEASURE PATIENT RELEVANT OUTCOMES?

IQWIG AND THE EFFICIENCY FRONTIER – HOW CAN WE MEASURE PATIENT RELEVANT OUTCOMES?
Olaf Pirk PhD, MD
Principal, Health Economics & Outcomes Research, IMS Health, Nuremberg, Germany

IP9: HOW SHOULD HTA METHODS BE ADAPTED TO MEET THE RISING EXPECTATIONS OF DECISION MAKERS FOR MEDICAL DEVICES AND DIAGNOSTICS REIMBURSEMENT?

HOW SHOULD HTA METHODS BE ADAPTED TO MEET THE RISING EXPECTATIONS OF DECISION MAKERS FOR MEDICAL DEVICES AND DIAGNOSTICS REIMBURSEMENT?
Adrian Griffin MSc
VP Strategic Affairs, LifeScan EMEA, Buckinghamshire, UK

IP10: ESTIMATING THE COST-EFFECTIVENESS OF VACCINES – IS THE HEALTH ECONOMIST’S STANDARD TOOLBOX SUFFICIENTLY EQUIPPED?

ECONOMIC EVALUATION OF INFECTIOUS DISEASE PREVENTION
Philippe Beutels MSc, PhD
Professor, Centre for Health Economics Research and Modeling Infectious Diseases (CHERMID), Centre for the Evaluation of Vaccines (CEV), University of Antwerp, Antwerp, Belgium

Economic Evaluation of Infectious Disease Prevention
Matthew Taylor PhD
Senior Consultant, York Health Economics Consortium, University of York, York, UK


12th Annual European Congress Main Page